Marco Montilo

Effect of dose modifications on response to duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the DUO trial

Purpose of the Study: Duvelisib, a first-in-class oral dual PI3K-, inhibitor, was approved by the FDA for treatment of relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL)/smal...

Julio Delgado ;

Bryone J. Kuss ;

Constantine S. Tam ;

Francesc Bosch ;

Ulrich Jager ;

Paolo Ghia ;

Florence Cymalista ;

Stephan Stilgenbauer ;

Fritz Offner ;

David T. Weaver ;

Stephanie Lustgarten ;

Hagop Youssoufian ;

Ian W. Flinn ;

Nicole Lamanna ;

Marco Montilo ;

Matthew S. Davids , MD, MMSc;

Gabriel Etienne ;

10/22/2019

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

November 6 ⁠–⁠ November 8

November 7 ⁠–⁠ November 10

November 8

November 8 ⁠–⁠ November 10

November 13 ⁠–⁠ November 16

November 14 ⁠–⁠ November 15

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

See Full Calendar

Marco Montilo

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products